Skip to main content

Table 3 Summary of samalizumab PK parameters

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Dose   No. of patients Tmax
(h)
Cmax
(μg/mL)
AUC
(μg·h/mL)
T1/2
(h)
CL
(mL/h)
Vz
(mL)
100 mg/m2   5 2.21 ± 3.25 38.9 ± 4.75 2792 ± 2227 85.1 ± 60.9 101 ± 67.5 8246 ± 1499
200 mg/m2   3 1.23 ± 0.09 90.2 ± 10.6 11,957 ± 6599 107 ± 45.2 36.3 ± 14.9 4943 ± 469
300 mg/m2   3 4.71 ± 4.65 109 ± 42.7 36,636 ± 11,540 371 ± 48.9 16.9 ± 4.15 9186 ± 3215
400 mg/m2   3 8.93 ± 11.1 135 ± 37.8 37,679 ± 7219 245 ± 33.9 21.3 ± 4.61 7391 ± 897
500 mg/m2   7 3.87 ± 1.85 211 ± 44.9 62,898 ± 24,222 365 ± 172 19.5 ± 10.4 8490 ± 1715
600 mg/m2   1 3.08 288 134,629 538 7.58 5880
  1. Values are presented as Mean ± SD. The samalizumab serum concentration assay had a lower limit of quantification of 3.70 μg/mL and the standard curve ranged from 3.7 to 100 μg/mL Assay precision was 1 to 18% and accuracy was 93.2 to 127.8% (Mean % of recovery)